{"filing":{"accession_number":"0001193125-26-330568","cik":"0001796280","ticker":"ORIC","company_name":"Oric Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"oric-20260803.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1796280/000119312526330568/oric-20260803.htm"},"events":[{"id":23358,"run_id":21119,"accession_number":"0001193125-26-330568","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"ORIC Pharmaceuticals issued a press release on August 3, 2026 announcing financial results for the fiscal quarter ended June 30, 2026, including condensed balance sheets and statements of operations showing R\u0026D expenses of $36.3 million (Q2 2026 vs. $30.5 million Q2 2025), G\u0026A expenses of $9.0 million, and a net loss of $41.5 million. The disclosure is filed under Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings releases.","company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23560,"accession_number":"0001193125-26-330568","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ORIC Pharmaceuticals issued a press release on August 3, 2026 announcing financial results for the fiscal quarter ended June 30, 2026, including condensed balance sheets and statements of operations showing R\u0026D expenses of $36.3 million (Q2 2026 vs. $30.5 million Q2 2025), G\u0026A expenses of $9.0 million, and a net loss of $41.5 million. The disclosure is filed under Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:22:07.731712+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23560,"accession_number":"0001193125-26-330568","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ORIC Pharmaceuticals issued a press release on August 3, 2026 announcing financial results for the fiscal quarter ended June 30, 2026, including condensed balance sheets and statements of operations showing R\u0026D expenses of $36.3 million (Q2 2026 vs. $30.5 million Q2 2025), G\u0026A expenses of $9.0 million, and a net loss of $41.5 million. The disclosure is filed under Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:22:07.731712+00:00","company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","filing_date":"2026-08-03"}]}